Introduction
============

Renal cell carcinoma (RCC) is the most frequently occurring type of kidney cancer (85%). RCC has the highest malignancy and mortality rates among all types of urogenital cancer. Clear cell renal cell carcinoma (CCRCC) is the most common type of RCC, accounting for almost 85% of the reported cases of RCC ([@b1-ol-0-0-11165]). Although improvements in both chemotherapy and surgical techniques have been made, the prognosis of certain patients with CCRCC remains poor, and advanced CCRCC continues to be fatal due to tumor recurrence and metastasis ([@b2-ol-0-0-11165]). In addition, the pathogenesis of CCRCC remains unknown, and the underlying molecular mechanisms are complex. Therefore, investigating the pathogenesis and identifying novel biomarkers is of the utmost importance for the early detection and treatment of patients with CCRCC.

Thioredoxin interacting protein (TXNIP) is a small 38 kDa protein that was identified to be a vitamin D3-induced gene, and it was originally named vitamin D3 upregulated protein 1 ([@b3-ol-0-0-11165]). Another study indicated that TXNIP binds to and negatively modulates the activity of thioredoxin (TRX) ([@b4-ol-0-0-11165]). A previous study demonstrated that TXNIP deficiency stimulates transforming growth factor-β (TGF-β)-induced epithelial-mesenchymal transition, indicating that TXNIP may suppress tumor progression ([@b5-ol-0-0-11165]). In gastroesophageal adenocarcinoma, TXNIP has been identified to be an independent prognostic factor for distant metastasis-free survival and overall survival ([@b6-ol-0-0-11165]). Additionally, TXNIP has been demonstrated to serve a role as a tumor suppressor gene by directly inducing the expression of the tumor suppressor protein p53 ([@b7-ol-0-0-11165]). Accumulating evidence has demonstrated that TXNIP is abnormally expressed in a variety of malignant tumors, and functions as a tumor suppressor ([@b8-ol-0-0-11165]) in malignancies such as hepatoma ([@b9-ol-0-0-11165]), breast cancer ([@b10-ol-0-0-11165]), pancreatic ductal adenocarcinoma ([@b11-ol-0-0-11165]) and esophageal adenocarcinoma ([@b12-ol-0-0-11165]). However, the association between TXNIP and CCRCC is yet to be fully elucidated.

In the present study, the association between TXNIP expression and the clinicopathological characteristics of patients with CCRCC was evaluated, and the prognostic value of TXNIP in CCRCC was analyzed based on data obtained from The Cancer Genome Atlas (TCGA). Furthermore, the biological pathways associated with TXNIP were determined using Gene Set Enrichment Analysis (GSEA), which may provide further insight into the molecular mechanisms of CCRCC.

Patients and methods
====================

### RNA sequencing and clinical information

The RNA sequencing data and corresponding clinical data were collected from TCGA database (<https://cancergenome.nih.gov/>). A total of 539 CCRCC tissues and 72 normal tissues were obtained. Ultimately, 529 cases were selected for subsequent analysis, while cases without clinical prognostic information were excluded. Detailed clinical information, including age at diagnosis, sex, T stage, lymph-node status, metastasis and clinical stage was recorded. Any information that was unavailable or unknown was regarded as missing.

### GSEA

GSEA was used to evaluate whether an *a priori* set of genes exhibited significant differential expression between the high- and low-TXNIP groups ([@b13-ol-0-0-11165],[@b14-ol-0-0-11165]). The TXNIP mRNA expression level was used as a phenotype label. In total, 1,000 gene set permutations were performed for each analysis. The nominal P-value, false discovery rate (FDR) and normalized enrichment scores (NES) were used to classify the signaling pathways enriched in each phenotype.

### Statistical analysis

All statistical analyses were performed using R (v.3.6.0) software and SPSS v.24.0 software (IBM Corp.). Comparison of the expression levels of TXNIP between CCRCC and normal groups was performed using an unpaired Student\'s t-test, and paracancerous groups with a paired t-test. Based on the median value for TXNIP expression (274.17), patients with CCRCC were divided into high- and low-risk groups. Analysis of variance followed by a Least Significance Difference post hoc test and logistic regression were used to analyze the TXNIP expression and pathological parameters of CCRCC. Kaplan-Meier survival analysis was used with the log-rank test to compare the overall survival between the high- and low-TXNIP expression groups. The univariate and multivariate Cox proportional hazards model was used to evaluate the prognostic value of TXNIP expression. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Downregulated TXNIP expression in CCRCC

TXNIP expression was investigated in 539 CCRCC tissues and 72 normal tissues. The results indicated that TXNIP expression was decreased in the CCRCC tissues compared with in the normal tissues (P\<0.001; [Fig. 1A](#f1-ol-0-0-11165){ref-type="fig"}). Furthermore, the expression of TXNIP in 72 pairs of CCRCC tissue and paracancerous tissue were also investigated; the results revealed that TXNIP was downregulated in CCRCC tissues (P\<0.01; [Fig. 1B](#f1-ol-0-0-11165){ref-type="fig"}), demonstrating that TXNIP may suppress CCRCC tumorigenesis.

### Patient clinical characteristics

From TCGA database, 529 tumors with both gene expression data and clinical parameters were analyzed. The clinical characteristics of the patients including age, sex, metastasis, lymph-node status, clinical stage, T stage and grade are presented in [Table I](#tI-ol-0-0-11165){ref-type="table"}.

### Associations between TXNIP expression and the clinical characteristics of patients with CCRCC

A total of 529 CCRCC samples with TXNIP expression data from TCGA database were analyzed. As shown in [Fig. 2A-D](#f2-ol-0-0-11165){ref-type="fig"}, the decreased expression of TXNIP was significantly associated with T stage (P\<0.001), lymph-node status (P\<0.05), clinical stage (P\<0.001) and grade (P\<0.001).

Univariate analysis using logistic regression indicated that decreased TXNIP expression was associated with poor prognostic features ([Table II](#tII-ol-0-0-11165){ref-type="table"}). The decreased expression of TXNIP in CCRCC was significantly associated with clinical stage \[OR=0.509 for III vs. I (P=0.002); OR=0.527 for IV vs. I (P=0.012)\], T stage \[OR=0.552 for T3 vs. T1 (P=0.002)\] and grade \[OR=0.261 for G4 vs. G1 (P=0.027); [Table II](#tII-ol-0-0-11165){ref-type="table"}\]. These results revealed that cases of CCRCC with a low TXNIP expression level were associated with poor clinical outcome.

### Univariate and multivariate analysis of survival

As indicated in [Fig. 2E](#f2-ol-0-0-11165){ref-type="fig"}, Kaplan-Meier survival analysis indicated that CCRCC with low TXNIP expression was associated with a poorer prognosis compared with CCRCC with high TXNIP expression (P=0.002). In univariate analysis, age (HR=1.033; P\<0.001), metastasis (HR=4.284; P\<0.001), clinical stage (HR=1.889; P\<0.001), T stage (HR=1.941; P\<0.001), grade (HR=2.293; P\<0.001) and TXNIP expression (HR=0.652; P\<0.001) were associated with the overall survival of patients with CCRCC. Using multivariate analysis, TXNIP expression was revealed to be an independent predictor of the prognosis of patients with CCRCC (HR=0.733; P=0.009; [Table III](#tIII-ol-0-0-11165){ref-type="table"}).

### Identification of TXNIP-associated signaling pathways using GSEA

To elucidate the signaling pathway associated with TXNIP, GSEA was performed between the high- and low-TXNIP expression datasets. Significant differences were observed in the enrichment of the Molecular Signatures Database collection (FDR\<0.05, and normalized P\<0.05). Based on their NES, normalized (NOM) P-values and FDR q-values, 6 pathways that exhibited significant differential enrichment in the TXNIP-high expression phenotype were identified, including the WNT signaling pathway, the mitogen-activated protein kinase (MAPK) signaling pathway, the phosphatidylinositol signaling system, the TGF-β signaling pathway, autophagy and the Janus kinase (JAK)-STAT signaling pathway ([Fig. 3](#f3-ol-0-0-11165){ref-type="fig"}; [Table IV](#tIV-ol-0-0-11165){ref-type="table"}).

Discussion
==========

Previously, a number of studies have indicated that TXNIP functions as a tumor-suppressor gene in various types of cancer ([@b8-ol-0-0-11165],[@b15-ol-0-0-11165]). Numerous studies have confirmed that the overexpression of TXNIP results in an increase in the levels of apoptosis, the suppression of cell proliferation, decreased metastasis and suppressed tumor growth ([@b16-ol-0-0-11165]--[@b20-ol-0-0-11165]). However, little is known about the association between TXNIP and CCRCC. In the present study, the expression of TXNIP in CCRCC tissues and its potential prognostic value were investigated.

In addition, CCRCC high-throughput RNA-sequencing data from TCGA were also investigated. TXNIP was revealed to be significantly downregulated in CCRCC tissues compared with adjacent normal or normal tissues. In addition, the decreased expression of TXNIP in CCRCC was evidently associated with T stage, lymph-node status, clinical stage, grade and a poor prognosis. To further elucidate the signaling pathways associated with TXNIP, GSEA was performed between the high- and low-TXNIP expression datasets. A total of 6 pathways were identified, which exhibited significant differential enrichment in the TXNIP-high expression phenotype, including the WNT, MAPK, phosphatidylinositol and TGF-β signaling pathways, as well as autophagy and the JAK-STAT signaling pathway. This indicates that TXNIP may serve as a potential therapeutic and prognostic target in CCRCC.

TXNIP is considered to be a tumor suppressor and is essential for regulating the redox status of cells by interacting with TRX. Feingold *et al* ([@b12-ol-0-0-11165]) showed that the overexpression of TXNIP reduces the clonogenicity and proliferation of esophageal adenocarcinoma cells. TXNIP deficiency results in the high viability and estrogen-induced growth of breast tumors ([@b21-ol-0-0-11165]). In addition, the overexpression of TXNIP may lead to attenuated tumor growth and markedly diminished metastasis in orthotopic anaplastic thyroid cancer ([@b19-ol-0-0-11165]). Furthermore, TXNIP overexpression induces apoptosis and represses proliferation by triggering mitochondrial-mediated reactive oxygen species generation and MAPK signaling pathway activation in SMMC7221 cells ([@b16-ol-0-0-11165]). In addition, the overexpression of TXNIP has been demonstrated to be associated with the improved overall survival rate of patients with breast cancer ([@b22-ol-0-0-11165]). Similarly, the present study indicated that TXNIP is downregulated in CCRCC tissues, and is associated with T stage, lymph-node status, clinical stage, grade, survival and poor prognosis, highlighting the crucial role of TXNIP in the progression of CCRCC.

To further observe the molecular functions of TXNIP, GSEA was conducted, revealing that TXNIP was able to regulate a number of crucial signaling pathways, including the WNT signaling pathway, MAPK signaling pathway, phosphatidylinositol signaling system, the TGF-β signaling pathway, autophagy and the JAK-STAT signaling pathway. Wang *et al* ([@b23-ol-0-0-11165]) revealed that the Wnt/β-catenin signaling axis serves a key role in regulating cell proliferation in CCRCC. Hong *et al* ([@b24-ol-0-0-11165]) identified that the activation of the MAPK signaling pathway in RCC enhanced cell viability and invasiveness. TGF-β serves a crucial role in regulating various biological functions, including cell differentiation, proliferation, metastasis, angiogenesis, cellular microenvironment and immune surveillance ([@b25-ol-0-0-11165]). TGF-β has also been indicated to promote the aggressive behavior and invasion of CCRCC ([@b26-ol-0-0-11165]). In addition, there is evidence to indicate that autophagy is associated with the development of CCRCC, including cell death, proliferation and metastasis ([@b27-ol-0-0-11165]--[@b29-ol-0-0-11165]). It has also been suggested that the resistance of RCC to interferon-α is associated with defective JAK-STAT activation ([@b30-ol-0-0-11165]). However, further mechanistic studies are required to validate the regulatory mechanisms of TXNIP in CCRCC, which may provide novel therapeutic approaches for CCRCC.

Although the results of the present study improved understanding of the association between TXNIP and CCRCC, there were several limitations: Firstly, only TCGA data were analyzed, and clinical specimen verification was not performed. Secondly, the association between TXNIP mRNA and TXNIP protein expression was not assessed, and should be included in further studies.

In conclusion, the present study identified that TXNIP expression may be a potential prognostic marker for patients with CCRCC. However, further functional studies are required to explore the molecular mechanisms of TXNIP in CCRCC progression.

The results presented are in whole based upon data generated by the TCGA Research Network: <https://www.cancer.gov/tcga>.
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![TXNIP is markedly downregulated in CCRCC tissues compared with normal or paracancerous tissues. (A) TXNIP expression in cancer tissues was significantly decreased compared with normal tissues. \*\*\*P\<0.001. (B) TXNIP expression was significantly decreased in CCRCC compared with 72 pairs of paracancerous tissues. \*\*P\<0.01. TXNIP, thioredoxin interacting protein; CCRCC, clear cell renal cell carcinoma.](ol-19-01-0763-g00){#f1-ol-0-0-11165}

![Association of TXNIP expression with patient clinicopathological characteristics. (A) T stage. (B) Lymph-node status. (C) Clinical stage. (D) Grade. (E) Effect of TXNIP expression on the overall survival of patients with CCRCC in The Cancer Genome Atlas datasets. TXNIP, thioredoxin interacting protein; CCRCC, clear cell renal cell carcinoma. \*P\<0.05 and \*\*\*P\<0.001.](ol-19-01-0763-g01){#f2-ol-0-0-11165}

![Enrichment plots from GSEA. GSEA results indicated that the (A) WNT signaling pathway, (B) MAPK signaling pathway, (C) phosphatidylinositol signaling system, (D) TGF-β signaling pathway, (E) autophagy, and (F) the JAK-STAT signaling pathway were differentially enriched in CCRCC with high TXNIP expression. NES, normalized enrichment score; NOM p-val, normalized P-value; FDR q-val, false discovery rate q-value; GSEA, Gene Set Enrichment Analysis; TXNIP, thioredoxin interacting protein; CCRCC, clear cell renal cell carcinoma; MAPK, mitogen-activated protein kinase; TGF-β, transforming growth factor-β; JAK, Janus kinase.](ol-19-01-0763-g02){#f3-ol-0-0-11165}

###### 

Clinical characteristics of patients with renal clear cell carcinoma.

  Variable                  Cases, n   Percentage
  ------------------------- ---------- ------------
  Age at diagnosis, years              
    ≤60                     262        49.53
    \>60                    267        50.47
  Sex                                  
    Male                    341        64.46
    Female                  188        35.54
  Metastasis                           
    M0                      423        84.43
    M1                      78         15.57
  Lymph-node status                    
    N0                      239        93.73
    N1                      16         6.27
  Clinical stage                       
    I                       265        50.09
    II                      56         10.59
    III                     125        23.63
    IV                      83         15.69
  T stage                              
    T1                      271        51.23
    T2                      68         12.85
    T3                      179        33.84
    T4                      11         2.08
  Grade                                
    G1                      14         2.67
    G2                      227        43.32
    G3                      206        39.31
    G4                      77         14.70

###### 

TXNIP expression is associated with patient clinical pathological characteristics.

  Clinical characteristics        Total   Odds ratio in TXNIP expression   P-value
  ------------------------------- ------- -------------------------------- ---------
  Age (continuous)                529     0.991 (0.977--1.005)             0.250
  Sex (female vs. male)           529     1.261 (0.883--1.806)             0.203
  Metastasis ((M1 vs. M0)         501     0.611 (0.357--1.037)             0.069
  Lymph-node status (N1 vs. N0)   255     0.737 (0.451--1.196)             0.219
  Clinical stage (II vs. I)       321     0.669 (0.375--1.188)             0.170
  Clinical stage (III vs. I)      390     0.509 (0.329--0.784)             0.002
  Clinical stage (IV vs. I)       348     0.527 (0.317--0.867)             0.012
  T stage (T2 vs. T1)             339     0.611 (0.357--1.037)             0.069
  T stage (T3 vs. T1)             450     0.552 (0.376--0.808)             0.002
  T stage (T4 vs. T1)             282     0.281 (0.060--0.994)             0.065
  Grade (G2 vs. G1)               241     0.745 (0.223--2.226)             0.607
  Grade (G3 vs. G1)               220     0.504 (0.151--1.511)             0.234
  Grade (G4 vs. G1)               91      0.261 (0.073--0.839)             0.027

Data were analyzed using logistic regression. TXNIP, thioredoxin interacting protein.

###### 

Univariate and multivariate cox regression analysis of patients with renal clear cell carcinoma.

                      Univariate analysis    Multivariate analysis                          
  ------------------- ---------------------- ----------------------- ---------------------- ---------
  Age                 1.033 (1.019--1.047)   \<0.001                 1.035 (1.021--1.051)   \<0.001
  Sex                 1.074 (0.779--1.481)   0.663                   --                     --
  Metastasis          4.284 (3.106--5.908)   \<0.001                 1.033 (0.664--2.555)   0.442
  Lymph-node status   0.865 (0.739--1.012)   0.069                   --                     --
  Clinical stage      1.889 (1.649--2.164)   \<0.001                 1.687 (1.078--2.640)   0.022
  T stage             1.941 (1.639--2.299)   \<0.001                 0.864 (0.574--1.301)   0.485
  Grade               2.293 (1.854--2.836)   \<0.001                 1.462 (1.148--1.861)   0.002
  TXNIP               0.652 (0.534--0.797)   \<0.001                 0.733 (0.581--0.926)   0.009

TXNIP, thioredoxin interacting protein; HR, hazard ratio; CI, confidence interval.

###### 

Gene sets enriched in the high expression phenotype group.

  Gene set name                                NES      NOM P-value   FDR q-value
  -------------------------------------------- -------- ------------- -------------
  KEGG_WNT_SIGNALING_PATHWAY                   −2.278   \<0.001       0.002
  KEGG_MAPK_SIGNALING_PATHWAY                  −2.208   \<0.001       0.002
  KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM   −2.210   \<0.001       0.002
  KEGG_TGF_BETA_SIGNALING_PATHWAY              −2.194   \<0.001       0.002
  KEGG_REGULATION_OF_AUTOPHAGY                 −2.211   \<0.001       0.003
  KEGG_JAK_STAT_SIGNALING_PATHWAY              −2.222   \<0.001       0.003

MSigDB collection: c2. cp. kegg. v6. 2. symbols. gmt. MAPK, mitogen-activated protein kinase; TGF-BETA, transforming growth factor-β; JAK, janus kinase; NES, normalized enrichment score; NOM p-val, normalized P-value; FDR q-val, false discovery rate q-value; MSigDB, Molecular Signatures Database.
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